Company: ARWR
Filing Date: 2025-02-10
Form Type: 10-Q
Source: 0001628280-25-004634
Chunk: 13

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-02-10
Form: 10-Q
Item: Part I, Item 1
Chunk 13
---
controlling Interest and Stockholders’ Equity$1,013,694 $1,139,802  

The accompanying notes are an integral part of these unaudited consolidated financial statements. 

1

Arrowhead Pharmaceuticals, Inc.

Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except per share amounts)

(unaudited) 

Three Months Ended December 31,20242023Revenue$2,500 $3,551 Operating expenses:Research and development137,002 116,491 General and administrative26,910 23,605 Total operating expenses163,912 140,096 Operating loss(161,412)(136,545)Other income (expense):Interest income7,602 2,802 Interest expense(21,646)(5,367)Other, net341 421 Total other expense(13,703)(2,144)Loss before income tax expense and noncontrolling interest(175,115)(138,689)Income tax expense (benefit) 103 (3,313)Net loss including noncontrolling interest$(175,218)$(135,376)Net loss attributable to noncontrolling interest, net of tax(2,133)(2,512)Net loss attributable to Arrowhead Pharmaceuticals, Inc.$(173,085)$(132,864)Net loss per share attributable to Arrowhead Pharmaceuticals, Inc.:Basic$(1.39)$(1.24)Diluted$(1.39)$(1.24)Weighted-average shares used in calculatingBasic124,848 107,415 Diluted124,848 107,415 Other comprehensive loss, net of tax:Unrealized (losses) gains on available-for-sale securities(507)1,909 Foreign currency translation adjustments(106)58 Comprehensive loss$(175,831)$(133,409)

The accompanying notes are an integral part of these unaudited consolidated financial statements. 

2

Arrowhead Pharmaceuticals, Inc.

Consolidated Statements of Stockholders’ Equity 

(in thousands)

(unaudited)

CommonStockAmount ($)AdditionalPaid-InCapitalAccumulated Other Comprehensive IncomeAccumulatedDeficitNon-controlling InterestTotalBalance at September 30, 2024124,376 $217 $1,806,000 $4,750 $(1,625,523)$5,619 $191,063 Stock-based compensation— — 15,209 —